Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year ...

The Duke of Sussex spoke in depth about his drug use in his explosive memoir Spare - and it's caused issues ever since the ...

Black Diamond resident Ross Heinzinger recently pleaded ... when a law officer spotted them passed out in a vehicle with drug paraphernalia in plain view; a search warrant later allowed police ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

The strategic worldwide licensing agreement grants Servier the rights to develop and commercialize BDTX-4933, a therapy currently in Phase 1 development. Under the terms of the deal, Black Diamond ...

March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq ... Planning to solicit U.S. Food and Drug Administration (FDA) feedback on a potential pivotal registrational path for BDTX ...

This recall involves all BD Vision Harnesses. This lightweight harness is designed for technical alpine and ice climbs. All ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with bes ...